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Abstract
The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise. Although NETs are a heterogeneous 
group of tumours, they have some similar properties, for example, that they can concentrate neuroamines and tend 
to have a high degree of somatostatin receptor (SSR) expression. These mechanisms can be exploited and this article 
discusses the important role of radionculide imaging and radionculide therapy in the management of NETs based on 
these mechanisms. This article reviews the current literature and discusses the role of radionuclide imaging in NETs 
both in terms of SSR imaging and neuroamine (metaiodobenzylguanidine [MIBG]) imaging. We discuss state-of-
the-art 68Ga-radiopeptide imaging and indications for it use. We also discuss the role of 18F-FDG and other tracers 
in the management of NETs. The second half of the article focuses on radiotargeted treatment of NETs, discussing 
I-131 MIBG therapy and focussing on the emergence of peptide receptor radionuclide therapy. We discuss the clinical 
results, toxicities and patient selection for PRRT.
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Introduction
Neuroendocrine tumours (NETs) are perceived to be 
rare tumours. However, the incidence is on the rise from 
1973 (1.09/100,000) to 2004 (5.25/100,000).[1] There are 
several possibilities for this increase such as increased (a) 
awareness and diagnosis by clinicians, (b) detection due 
modern imaging and immunohistopathological techniques 
and (c) possibly a true increase in incidence.[2] In general, 
NETs tend to be slow growing. However, the prevalence of 
people with NET is increasing: 35/100,000 and is currently 
reported to be the second most prevalent gastrointestinal 
neoplasm (second to colon cancer).
NETs are a heterogeneous group of tumours graded 
histologically according to their proliferative activity 
and number of mitoses/high-power field into low-, 
intermediate- and high-grade (G3) tumours. NETs have 
similar properties in that the majority of well-differentiated 
and some high-grade tumours can concentrate neuroamines 
and tend to have a high degree of somatostatin receptor 
(SSR) expression. This high degree of SSR expression and 
neuroamine concentration can be exploited both in terms 
of imaging and therapy using radiolabelled somatostatin 
analogues and radiolabelled metaiodobenzylguanidine 
(MIBG) (catecholamine analogue). This article explores 
the important role of nuclear medicine in both the 
diagnosis and treatment of NETs.
Diagnosis
The diagnosis of NETs is based on clinical assessment, 
biochemical evaluation, topographic including radiological 
investigations and, finally, histological confirmation.
Cross-sectional imaging (computed tomography/
magnetic resonance imaging [CT/MRI])
Cross-sectional imaging is generally the first-line 
imaging modality, which is often used to stage/restage 
patients with NETs and to assess response to treatment. 
A triple-phase CT study is essential (non-contrast scan 
and 2 contrast-enhanced studies: An arterial phase and a 
portovenous phase), as liver metastases may be isodense 
on portovenous phase and often show characteristic 
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arterial enhancement. Arterial and portovenous phase CT 
is particularly good at demonstrating vascular involvement 
(evaluate potential resectability of a primary tumour/
mesenteric mass). In general, MRI is superior to CT in 
diagnosing liver metastases.
Functional imaging
Functional imaging with nuclear medicine techniques in 
NETs includes MIBG imaging (I-123, 131I), SSR imaging 
(111 in-pentetreotide, 68 Gallium-DOTA), Fluorine-18-
L-dihydroxyphenylalanine (18F-DOPA) and F-18-FDG 
PET/CT.
I-123/I-131-MIBG imaging
MIBG is an alkylguanidine (catecholamine analogue) 
concentrates by 1 active amine uptake mechanism in the cell 
membrane of sympathomedullary tissues and is stored within 
cytoplasmic catecholamine storage vesicles.[3-5] Radioiodinated 
MIBG is well established in the scintigraphic detection of 
catecholamine-secreting tumours (pheochromocytoma and 
paraganglioma), with overall sensitivity around 90%. MIBG 
imaging has also been used in NETs, with rates of positivity 
at around 70%.[6] In several studies comparing 123I-MIBG 
and 111Indium (111In)-pentetreotide, 111In-pentetreotide 
was found to be more sensitive for the detection of disease 
in NETs.[7-9] The majority of NETs thus are imaged not with 
MIBG but with SSR scintigraphy (SSR). Although MIBG 
imaging may not be useful in staging a patient, it may be useful 
determine therapeutic options in some patients i.e. I-131 MIBG 
radionuclide therapy [Figure 1].
SSR scintigraphy (SRS)
SSRs are expressed in a number of normal cells including 
the pituitary, thyroid, spleen, kidney and peripheral 
nervous system. In addition, several tumours have been 
found to express SSRs, with a high incidence and density 
of receptors found particularly in NETs.[10] SSR subtype-2 
is relatively overexpressed SSR in NETs.[10]
When to use SSR imaging
The main application of SSR imaging is to accurately 
stage disease, follow up and restage patients with known 
disease, determine SSR receptor status so that patients can 
be selected for “cold” or radiotargeted therapy and assess 
response to treatment.
Single-photon emission tomography SRS imaging
SSR imaging was first introduced in the late 1980s.[2] The 
first somatostatin analogue used for imaging of NETs was 
octreotide (having a predominant affinity for SSR subtypes 
2 and 5 [SSR-2 and SSR-5] with lesser affinity for SSR 
subtype 3 [SSR-3]) and remains as a most popular analogues 
used for imaging NETs. Octreotide was subsequently 
labelled with 111In. It has a half-life of 68 h and delayed 
imaging (24 or 48 h) is usually required to ensure a 
reduction in background activity caused by clearance 
through the renal and hepatobiliary system. Labelling of 
somatostatin analogues with the most commonly used 
radionuclide in nuclear medicine (Tc-99m) has also been 
achieved.[11] 99mTc-hydrazinonicotinyl-Tyr3-octreotide 
(99mTc-HYNIC-TOC) and 99mTc-hydrazinonicotinyl-
Tyr3-Thr8-octreotide (99mTc-HYNIC-TATE) have a 
predominant renal excretion (hepatobiliary excretion 
being negligible),[11] which make this agent suitable and 
attractive for imaging abdominal NETs.
Uptake of 111In-pentetreotide and Tc-99m-HYNIC-
peptides is seen in majority of patients (>75%) with 
gastroenteropancreatic NETs (GEPNETs), and major 
exceptions include insulinomas with a reduced sensitivity 
of 50–70% (probably due to small tumour size or poor 
expression of SSR-2 receptor) and poorly differentiated 
GEPNETs due to a lower expression of SSR-2.[12] More 
recent studies have showed that the use of hybrid SPECT/
Figure 1: Patient with midgut NET: I-123 metaiodobenzylguanidine 
(MIBG) study demonstrating good uptake at sites of diseases 
in the liver and abdomen. This, therefore, allowed patient to be 
treated with I-131 MIBG (shows similar distribution of disease)
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CT cameras/system may improve accuracy (>90%) and is 
reported to have clinical impact on patient management 
ranging from 14% to 64%.[13-17] Figure 2 demonstrates an 
example of an 111In-pentetreotide study.
PET SRS imaging
Gallium-68 (68Ga) imaging has become increasingly 
more popular recently in centres where PET/CT imaging 
is available. 68Ga has a convenient physical half-life 
of 68 min and decays by positron emission, giving the 
advantages of increased sensitivity and resolution that 
modern PET imaging allows. As it is produced by a 
68Ge–68Ga generator, it has the advantage of being 
independent of a cyclotron and each generator lasts for 
7–9 months. The short half-life allows completion of 
the study within 2–3 h of administration of tracer. In 
addition, the patient effective radiation dose is less than 
half (0.0167mSv/MBq) of 111In-DTPA-octreotide.[18] 
68Ga-linked somatostatin analogues have shown affinity 
towards SSRs and have been evaluated in vivo with several 
DOTA-related labelled somatostatin peptides including 
DOTA-TATE, DOTA-NOC, DOTA-TOC, DOTA-OC 
and DOTA-BOC (the first three of which being the 
most extensively studied/used clinically).[19] The main 
differences between these compounds are small changes in 
the peptide side chain, which result in different affinities to 
the SSR subtypes. DOTA-TATE has the highest affinity for 
SSR-2. In addition to expressing high affinity for SSR-2, 
DOTA-TOC has affinity for SSR-5, whereas DOTA-NOC 
has an additional affinity for SSR-3 and SSR-5 as well.[20]
There is no doubt that 68Ga-DOTA-peptides represent a 
significant evolution in SSR imaging over 111In-DTPA-
octreotide imaging. The advantages of improved resolution 
and sensitivity of PET and the stronger binding affinity 
for the SSR expressing tumour with DOTA-TATE have 
been demonstrated. In a recent study, it was shown that 
68Ga-DOTA-TATE changed the management in 36 of the 
51 (70%) patients who had either no uptake (35 patients) or 
low-grade uptake (15 patients) of 111In-octreotide. These 
patients were found to have a positive 68Ga-DOTA-TATE 
scan as part of their staging, enabling them to be treated 
with ‘cold’ or radiolabeled somatostatin analogue.
68Ga-DOTA-peptides may also be used to restage patients 
after peptide receptor radionuclide therapies (PRRT), 
with a reduction in uptake suggestive of a response to 
therapy. Rarely, a reduction in uptake on PET SRS may 
be as a result of tumour dedifferentiation (less expression 
of SSR), which may result in a false report of a response 
despite an increase in size of tumour. Correlation with the 
CT component of the study (or contrast-enhanced cross-
sectional imaging) helps to minimise this error.
18F-FDG PET/CT
Patients with NETs generally do not take up FDG due to 
the majority of PNETs having relatively low metabolic 
activity. In general, only tumours that are dedifferentiated 
or have a high proliferative index (i.e. G3 tumours) show 
marked uptake on 18F-FDG-PET/CT. 18F-FDG-PET/CT 
may thus have a role in staging and determining response 
to therapy (e.g., chemotherapy) in patients with high-grade 
tumours. Similarly, 18F-DOPA (precursor of dopamine) 
is less frequently used (selected cases) and is reported to 
be useful patients with insulinoma.
18F-DOPA and 11C-5-HTP
NETs have the ability to take up amine precursors. 
Amine precursors, for example, 5-hydroxy-L- tryptophan 
(5-HTP) and L-DOPA are incorporated and decarboxylated 
by the tumour cells by aromatic amino acid decarboxylase 
enzyme and stored in cytoplasmic secretory granules.
Figure 2: 111In-DTPA-octreotide whole-body and single-photon 
emission computed tomography/computed tomography (SPECT/
CT) study in a patient with metastatic pancreatic neuroendocrine 
tumour. The whole-body study demonstrates uptake in the left 
supraclavicular fossa, liver, and abdomen. SPECT/CT images 
demonstrate pancreatic primary and liver and splenic metastases
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18F-DOPA enters the catecholamine metabolic pathway of 
endogenous L-DOPA, both in the brain and peripherally. 
As NETs demonstrate increased activity of L-DOPA 
decarboxylase, they show a high uptake of 18F-DOPA. 
18F-DOPA is useful in imaging pheochromocytomas 
and paragangliomas with studies showing superiority to 
123I-MIBG imaging.[21,22] It is particularly useful in head 
and neck paragangliomas (sensitivity >90%). This is in 
part due to the high tumour:background ratio, with the 
absence of physiological uptake in adjacent structures.[23]
11C-5-HTP may also be useful in NETs, but due to it being 
labelled with 11C (half-life of 20 min, its use is restricted 
to only a few centres with an on-site cyclotron.
Radionuclide Therapy in NETs
131I-MIBG therapy
I-131-MIBG therapy for NETs has become less popular 
gradually over the past 10 years, with increased availability 
and relatively better uptake and wider indications of SSR 
therapies. However, it may still play an important role 
in patients, where their tumours do not express SSR and 
demonstrate good uptake on pre-uptake I-123-MIBG scan.
131I-MIBG efficacy
A summary of the most relevant studies in NETs is shown 
in Table 1. Approximately 40–50% of patients develop good 
symptomatic response to treatment. Not only many studies 
demonstrated progression-free survival (PFS) but also most 
studies showed an overall survival (OS) of over 40 months 
following MIBG therapy [Table 1]. Interestingly, Sywak 
et al.[24-29] compared two groups of 58 and 59 patients, 
respectively, with midgut NET. The first group was treated 
in a centre were 131I-mIBG was available, whilst the 
second group had no access to 131I-mIBG (or other radio-
targeted treatments). The 5-year survival rate in Group A 
was 63%versus 47% from Group B (P = 0.1).
131I-MIBG toxicity
The main toxicities are bone marrow suppression and 
myelodysplasias. Grade 3/4 bone marrow toxicity was 
seen in approximately 8% of patients (range 2–25%) with 
some relationship between the administered activity and 
the degree of toxicity. The most common form of bone 
marrow toxicity was thrombocytopaenia (11%) followed 
by leucopaenia (10%). Myelodysplasia is another possible 
rare side effect, which may occur in patients heavily pre-
treated with chemotherapy or radiotherapy.[24-29]
PRRT
PRRT is the term commonly used to describe treatment 
with β-emitting radiolabeled somatostatin analogues. PRRT 
has been performed with various somatostatin analogues 
labelled with 111Indium, 90Yttrium and 177Lutetium. From 
these, three main agents have been developed: 90 Yttrium-
DOTA octreotide (90Y-DOTATOC), 90 Yttrium-DOTA 
octreotate (90YDOTATATE) and 177 Lutetium-DOTA 
octreotate (177Lu-DOTATATE). The radionuclides used 
have different physical characteristics/properties, which 
may reflect on their efficacy and toxicity, for example, 
90Yttrium has a higher energy beta particle emission than 
177 Lutetium and may be suited to treating larger tumour 
masses but has some relatively increased toxicity.
The first radiolabelled PRRT was performed with 111In-
DTPA-octreotide. Although γ-rays (173 +247 KeV) of 
111In are useful for diagnostic imaging of NETs, the 
decay of 111In also produces Auger and conversion 
electrons. These electrons have a path length of 0.02–10 
and 200–500 mm, respectively.[30] In vitro PRRT studies 
have shown that the Auger electrons are responsible for the 
Table 1: Summary of major studies using 131I‑MIBG in metastatic NET radionuclide therapy










Safford (24) 10/75 ‑ 15/52 35/72 (49) 28 22
Nwosu (25) 11/40 ‑ 11/29 24/48 (56) 46 ‑
Gedik (26) 8/17 6/17 8/12 16/18 (89) 42 ‑
Gonias (27) 12845 24/45 24/34 ‑ ‑ 64
Navalkissoor (28) 3/37 22/37 3/20 15/34 (44) 48 33
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reported tumour responses with 111In-labelled somatostatin 
analogues. However, as 111In emits Auger electrons 
have mean particle ranges of <1 cell diameter, radiation 
emitted from a receptor-positive tumour cell is, therefore, 
unlikely to kill neighbouring receptor-negative cells. High 
activity 111In-DTPA-octreotide was the first radiolabelled 
somatostatin analogue to be used in humans but did not 
subsequently have widespread popularity with published 
studies not showing significant objective responses.[31,32]
90Y-based therapies
90Y-Lanreotide, 90Y-DOTATATE and 90Y-DOTATOC 
have been used. One multicentre trial (MAURITIUS) has 
been reported[33] in which targeted therapy was performed 
with 90Y-lanreotide (29). 8/39 (21%) patients with GEP 
NETS had an objective response to therapy, with a further 
17/39 (44%) having stable disease. This agent has also 
not found significant popularity. 90Y-DOTATATE and 
90Y-DOTATOC have been the most commonly used 
90Y-based radiopeptides in the treatment of NETs. 
A summary of the major studies using 90Y and 177Lu-
labeled radiopeptides is shown in Table 2.
90Y-90 DOTATATE/DOTATOC antitumour effects
Complete responses are rare. However, partial responses 
to treatment have been reported at between 9% and 37%, 
with disease progression reported only in 0%–13% of 
patients.[34-41] Patients treated are those with baseline 
progressive disease; thus, overall disease response/
stabilisation is seen in approximately 70–80% of 
patients.[34-41] In addition, the majority of studies have 
shown an excellent symptomatic response in >70% of 
patients.[34-41] Time to progression in reported studies 
ranged from 13 to 29 months. On multivariate analysis, 
Valkema et al. showed that the best predictors for OS are 
related to the baseline extent of disease (i.e., presence/ 
absence of liver metastases and the absence/presence of 
end-stage disease).
The Basel group found factors predicting longer survival 
which include morphologic response, clinical response 
and high tumour uptake of the radiopeptides.[35] Factors 
associated with worse survival include presence of bone 
or liver metastases and previous chemotherapy.
Toxicity
The main toxicities in these studies were bone marrow 
and renal impairment. The rate of permanent renal toxicity 
showed variation (range 1–9%). The highest recorded 
significant permanent renal toxicity was 9% from a 
Swiss study of over 1000 patients.[32] However, a recent 
multinational phase 2 trial reported renal toxicity at 2%.[38] 
Table 2: Summary of the major studies using 90Y and 177Lu‑labeled radiopeptides for radionuclide therapy






*Paganelli (34) 87 Milan 28 24 ‑ 14 months ‑ 
*Imhof (35) 1109 Basel 34 26 30 12.7 months 56% alive at 
23 months
*Valkema (36) 58 Rotterdam 9 29 58 29 months 37
*Gabriel (37) 60 Innsbruck 22 20 ‑ ‑ 
*Bushnell (38) 90 Multicentre 4 21 88 16.3 months 27
**Baum (39) 75 Germany 37 11 85 ‑ ‑
**Cwikla (40) 60 Poland 23 0 72 17 months 22 months
**Toumpanakis 
(41)




310 (504) Rotterdam 91/301 (29) 61/310 
(20)
‑ 33 46
Bodei (43) 51 Milan 15/51 (29) 9/51 
(18)




33 Perth 24 6 ‑ ‑ 88% at 24 
months
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The predictors for severe renal toxicity by the Swiss study 
were advancing age, baseline glomerular filtration rate 
and high uptake of tracer by the kidneys on the baseline 
111In-DTPA-octreotide scans.
Bone marrow toxicity is seen in approximately 12% of 
patients overall and is usually transient, presenting as either 
thrombocytopaenia or leucopaenia. Mild-to-moderate liver 
toxicity has also been recorded in 1% of patients, all of 
whom had extensive bilobar liver metastases.
177Lu-PRRT
The Rotterdam group is the largest institution to 
have published single centre outcomes using 177Lu-
DOTATATE. In this group’s most recent publication,[42] 
504 patients were treated (the majority with four cycles), 
with a maximum cumulative activity of 29.6 GBq.
Antitumour effects
In response analysis of 310 evaluable patients, 2% had a 
CR, 28% had a PR and a further 16% had a MR (using the 
Southwest Oncology Group Criteria). The median OS from 
treatment in these 310 patients was 46 months, whilst the 
median PFS was 33 months. On a Cox regression analysis, 
factors associated with poorer survival include progressive 
disease following treatment, the presence of liver/bony 
metastases, KPS score <70 and baseline weight loss. The 
Milan group has also reported similar response rates.[43]
Toxicity
The WHO grade 3/4 haematological toxicity occurred 
in 9.4% of 504 patients. 2/504 patients developed renal 
insufficiency. There were three patients with serious 
liver toxicity. One of these patients (with diffuse liver 
metastases) died of hepatic failure. Four patients developed 
myelodysplastic syndrome, one of which was likely to be 
related to previous alkylating chemotherapy. 6/504 patients 
were hospitalised soon after treatment with hormonal crisis. 
All six patients had extensive metastases and developed the 
hormonal-induced crisis after the first cycle of treatment.
Combination therapies
Combination therapies have been used in PRRT, 
either combining different radionuclides (i.e., 90Y and 
177Lu-labelled peptides) or combining PRRT with 
radiosensitising chemotherapy.
Treatment with radiosensitising chemotherapy has also 
been reported, with disease stabilisation seen in 96% of 
patients.[44]
Combination radiopeptide therapies have been performed 
as tandem therapies (i.e. administrating a combination 
of 90Y and 177Lu-radiopeptides at a single sitting) or 
sequential therapies with 90Y and 177Lu-radiopeptides.
Kunikowska et al. compared 90Y-DOTATATE to 
tandem treatment with 90Y- and 177Lu-DOTATATE in 
patients with NET.[45] They demonstrated a statistically 
significant increase in OS (median OS 26 months vs. not 
reached P = 0.027). This was achieved with no increase 
in toxicity.
Villard et al .  compared 237 patients who had 
90Y-DOTATOC versus 249 patients with 90Y-DOTATOC 
and 177Lu-DOTATOC sequentially.[46] They found that the 
combination therapy provided a significant increase in OS 
(47 months vs. 66 months P = 0.006). Significant renal 
toxicity was reported to increase from 8.9% to 11.2%.
Randomised controlled trials
PRRT has often been criticised due to the lack of RCT 
data. However, there is a multicentre phase III randomised 
controlled study of 177Lu-labelled DOTATATE versus 
high-dose Octreotide LAR in patients with inoperable, 
progressive, SSR positive, midgut carcinoid tumours. 
This study is currently recruiting patients in Europe and 
the United States. Hopefully, this may provide more 
robust data for the efficacy of Lu-177 DOTATATE in the 
near future.
Patient selection for PRRT in NETs
The therapeutic options in NETs should be discussed in 
a multidisciplinary setting, with the choice of the most 
appropriate technique made. In the majority of patients, 
surgical resection offers the only realistic possibility of 
cure, and thus, this should be considered the preferred 
option if curative surgery is feasible and the patient is 
fit enough.
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In patients with unresectable metastatic disease, 
there are various therapeutic options available. These 
include surgical debulking, chemotherapy, molecular 
targeted therapies (e.g., sunitinib and everolimus), 
interferon, somatostatin analogues, local therapies 
(e.g., radiofrequency ablation or embolisation) and PRRT.
Patient selection for PRRT in NETs should include histologically 
proven NET, who are SSR positive and have no surgical 
cure possible or patients are unsuitable for surgery. Patients 
should not have sufficient bone marrow reserve i.e., platelets 
>90,000/μL for 90Y and >75,000/μL for 177Lu.[47]
In addition, significant renal impairment is a relative 
contraindication, particularly if 90Y-radiopeptides are 
being used.
Those with too extensive disease, for example, extensive 
liver and bone metastases tend not to do as well with 
PRRT. Similarly, it has been shown that significantly 
poorer outcomes occur in patients with poor baseline 
functional status (i.e., Karnofsky performance score >70 
or ECOG <3–4).[42] Grading of the tumour also has a role in 
treatment with PRRT, as patients with G3 tumours should 
have cisplatin-based chemotherapy rather than PRRT as 
first line if they have progressive disease.
As NETs can be slow growing, the timing of treatment 
can be debatable. Patients with progressive disease or 
patients who are symptomatic despite cold somatostatin 
analogues should be the patients considered for therapy.
Conclusion
Nuclear medicine imaging and therapy have a vital role to 
play in the management of NETs. SSR imaging provides 
increased accuracy in staging patients with accuracies 
of >90% in well-differentiated tumours and allows a 
change in management compared with conventional 
imaging. Radionuclide therapies with radiolabeled 
somatostatin analogues and radioiodinated MIBG 
provides symptomatic benefit and increases survival in 
patients with metastatic NETs.
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